Navigation Links
InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
Date:9/25/2007

HAIFA, Israel, September 24 /PRNewswire/ -- InSightec Ltd. has begun the second stage of its FDA approved Phase I clinical trial for non-invasive treatment of brain tumors using MR guided Focused Ultrasound Surgery on the ExAblate(r) system.

The objectives of the study are to evaluate the safety of focused ultrasound delivered through an intact skull and to estimate the effect of the thermal ablation on the tumors. Patients with recurrent and inoperable glioblastomas or cerebral metastases are being recruited for this study.

ExAblate(r) uses high-intensity focused ultrasound waves to ablate (destroy) tissue in combination with Magnetic Resonance Imaging (MRI). The system provides visualization of the tumor and acoustic energy beam path as well as real time thermal feedback that allows the physician to monitor and control the treatment process.

Three patients with recurrent glioblastoma have already been treated at Brigham and Women's Hospital in Boston, evaluating the ability of the ExAblate system to safely reach a targeted tumor. Based on the safety profile submitted for review, the FDA recently approved the continuation of the trial.

"The ExAblate MRgFUS technology has significant potential as a non-invasive and non-ionizing tumor therapy, and offers an important potential alternative or adjunct to radiation therapy, and eventually, for brain surgery" says Ferenc Jolesz, MD Professor of Radiology, Brigham and Women's Hospital, Boston MA.

Dr. Peter Black, Professor of Neurosurgery at the Brigham and Women's Hospital and co-director of the study adds that "The challenge of brain tumor surgery is to achieve complete tumor removal or the greatest possible extent of tumor reduction without causing brain injury. This feasibility study will significantly advance our understanding of the potential of this technology for brain tumor treatment and if successful, prepare the way for a clinical efficacy study."

Further details of Ex
'/>"/>

SOURCE InSightec Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. What patients want: A story of choice, clinical trials & evidence-based medicine
3. ZyStor seeks to raise $15M for clinical trials
4. Prodesse begins clinical trials for flu virus detection
5. ConjuGon raises $3.3 million to fund clinical trials
6. Cancer-fighting agent heads for clinical trials
7. Quintessence cancer treatment chosen for clinical studies
8. Third Wave reports clinical growth, continued loss
9. Childrens expanding use of Sunrise Clinical Manager
10. Life-sciences conference to feature novel research with clinical potential
11. $14 million grant to drive clinical research at UW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 6, 2015  Endo International plc (NASDAQ: ENDP ) ... President and CEO, will present a corporate overview at the ... on Wednesday, May 20, 2015 at 11:00 a.m. ... for the event will be available on the Company,s website ... the link to the event. Participants should allow approximately 10 ...
(Date:5/6/2015)... -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company ... announced that Linda Powers , NW Bio CEO, will present ... for solid tumor cancers and the Company,s multiple clinical programs ... , , , DATE: , , , Thursday, May ... , 12:15 PM EDT , , , , LINK: ...
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine company ... grown under simulated embryonic conditions, will present new ... melanoma during the 2015 Society of Investigative Dermatology ... in Atlanta, GA. , Histogen has previously shown ... with anti-oncologic properties, with potential benefit in the ...
(Date:5/5/2015)... May 5, 2015  Blueprint Medicines (NASDAQ: ... initial public offering of 9,367,708 shares of common ... per share, including shares of common stock issued ... their option to purchase additional shares. The gross ... Medicines were approximately $168.6 million, before underwriting discounts and ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... Vermillion, Inc. (NASDAQ: VRML ), a molecular ... Trademark Office (USPTO) has issued a notice of allowance for ... claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that ... "This will be our third patent for biomarkers that ...
... in hospitals is increasing. Bacteria acquire resistance to antibiotics ... genes, either from the surrounding environment or from other ... research (University of Lisbon) and the Instituto Gulbenkian de ... resistance are playing out in the bacterium Escherichia ...
... signals, for the first time, to assist in braking, ... to the thousands of car accidents that are caused ... technique that attaches electrodes to the scalp , the ... traffic sensors, could detect a driver,s intention to break ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 3Bacterial resistance to antibiotics: The more they resist, the more they divide 2Put the brakes on using your brain power 2
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... German . , Berlin, 2 September 2009 - ... ecosystems - from forests and mangroves to wetlands and river ... change and climate-proofing vulnerable economies. This is among the ... Economics of Ecosystems and Biodiversity (TEEB), a project launched by ...
... JACKSONVILLE, Fla. In a biological rendition of fiction,s ... the Mayo Clinic campus in Florida and Harvard Medical School ... development can actually spur the spread of tumors. ... Molecular and Cellular Biology , found that FOXO3a, a transcription ...
... that comes to mind when people think of Alzheimer,s disease, ... and France, this might change. That,s because these researchers have ... might be the key that unlocks an entirely new class ... report published online in The FASEB Journal ( ...
Cached Biology News:Time to tap climate change-combating potential of the world's ecosystems 2Time to tap climate change-combating potential of the world's ecosystems 3Time to tap climate change-combating potential of the world's ecosystems 4Time to tap climate change-combating potential of the world's ecosystems 5Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side 2Scientists begin to untangle root cause of Alzheimer's disease 2
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... anti-phospho-FAK (Ser843) Immunogen: ... region encompassing the human, mouse, and ... Accession Number: NM_153831 ... evaluated by immunoblot. ...
Biology Products: